Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort

Table 3 The estimated ratio of the geometric mean number of days to recrudescence for each risk factor derived from linear regression analyses of 428 Plasmodium falciparum episodes among 354 pregnant women

		Univariable^a		Multivariable^a
Risk factor	Categories	N^b	Ratio of geometric means (95 % CI) [P-value]	N^b	Ratio of geometric means (95 % CI) [P-value]
Parity	Primiparous	93	0.99 (0.86, 1.14) [0.890]	79	1.03 (0.89, 1.19) [0.698]
Parity	Multiparous	256	1^c	212	1
Anti-malarial therapy	Artemisinin based	49	1.28 (1.09, 1.51) [0.003]	38	1.24 (1.07, 1.43) [0.003]
Anti-malarial therapy	Non-artemisinin based	300	1	253	1
Symptoms	Symptomatic	232	0.89 (0.77, 1.03) [0.120]	211	0.94 (0.80, 1.11) [0.459]
Symptoms	Asymptomatic	88	1	80	1
Therapy supervision	Unsupervised	86	0.83 (0.73, 0.94) [0.004]	81	0.83 (0.73, 0.95) [0.006]
Therapy supervision	Supervised	253	1	210	1
Intercalated P. vivax	Yes	28	2.19 (1.77, 2.72) [<0.001]	25	2.19 (1.76, 2.73) [<0.001]
Intercalated P. vivax	No	321	1	266	1
EGA (weeks)	349	349	1.00 (0.99, 1.00) [0.217]	291	1.00 (0.99, 1.00) [0.210]
Parasitaemia (m/L)^d	349	349	0.98 (0.97, 1.00) [0.079]	291	0.98 (0.96, 0.99) [0.014]
Haematocrit (%)	327	327	1.00 (0.99, 1.01) [0.618]	291	1.00 (0.99, 1.01) [0.654]

Combo, combination; Mono, monotherapy
^aOutcome is time to recrudescent infection and estimates are adjusted for age, weight and study period. Univariable, linear model included a single risk factor, age, weight and study period; Multivariable, linear model included all risk factors, age, weight and study period
^bThe total number of episodes (N) included in each analysis may differ from 428 due to missing risk factor data
^cIndicates reference group
^dParasitaemia was log₂ transformed. Estimate interpreted as a 0.98-fold decrease in geometric mean time to recrudescent Pf infection(s) for a doubling in parasitaemia

ISSN: 1475-2875